Decades from now, when we fully understand the biologic basis for the clinical heterogeneity of prostate cancer, we will think of the current era as the Golden Age of Prostate Nomograms. Driven by the ...

High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine ...

Our research addresses two critical gaps—clinical prediction and genetic causality—in prostate cancer patients who develop second malignancies. The nomogram offers physicians a practical tool to ...

Investigators recommend that clinicians consider PSA values in the context of other risk factors. Canadian researchers say it may be time to move beyond PSA-based predictions of prostate cancer risk.

Schematic representation of the study workflow. ICD-O-3, International Classification of Disease for Oncology, third edition; IPC, initial prostate cancer; OS ...

Dr. Luca Valle, assistant professor of radiation oncology at the David Geffen School of Medicine at UCLA, was awarded a $2.1 million grant from the U.S. Department of Veterans Affairs (VA) to develop ...

A patient’s life expectancy must be integrated into critical decision-making regarding treatment of patients with localized PCa. Accurately quantifying life expectancy in routine practice, however, is ...

No benefit was found in low-risk patients who underwent pelvic lymph node dissection (PLND). The extent of pelvic lymph node dissection (PLND) in patients undergoing radical prostatectomy (RP) for ...